可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 陈名道. 2型糖尿病及IGT人群心血管疾病的预防策略[J].国外医学·内分泌分册,2004,24(2):137-139.
[2] Reaven G. Insulin Resistance, Hypertension, and Coronary Heart Disease[J]. J Clin Hypertens (Greenwich) ,2003 ,5(4):269-274.
[3] Sekiguchi M, Kurabayashi M, Adachi H, et al. Usefulness of insulin resistance measured by homeostasis model assessment in predicting restenosis after coronary stent placement in nondiabetic patients[J]. Am J Cardiol,2004,93(7):920-922.
[4] 金文胜,潘长玉,陆菊明,等.葡萄糖耐量低减与动脉粥样硬化[J].中华内分泌代谢杂志,2004,20(2):136-139.
[5] Walcher D, Marx N. Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action[J]. Diab Vasc Dis Res,2004,1(2):76-81.
[6] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34) [J]. Lancet,1998,352(9131):854-865.
[7] Bastard JP, Pieroni L, Hainque B. Relationship between plasma plaminogen activator inhibitor 1 and insulin resistance[J]. Diabetes Metab Res Rev,2000,16(3):192-201.
[8] Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor1[J]. Metabolism,2002,51(4):471-476.
[9] Osman A,Otero J,Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes[J]. Am Heart J,2004,147(5):e23.
[10]Hadigan C, Meigs JB, Rabe J, et al. Increased PAI1 and tPA antigen levels are reduced with metformin therapy in HIVinfected patients with fat redistribution and insulin resistance[J]. J Clin Endocrinol Metab,2001, 86(2):939-943.
[11]易勇,陈玉成, 曾智. 冠脉支架内再狭窄防治研究进展[J].心脏杂志,2003,15(6):560-562.